Article info
PostScript
Letter
Vedolizumab safety in pregnancy and newborn outcomes
- Correspondence to Professor Daniel C Baumgart, Inflammatory Bowel Disease Center, Charité Medical Center, Virchow Hospital, Medical School of the Humboldt University, Berlin D-13344, Germany; daniel.baumgart{at}charite.de
Citation
Vedolizumab safety in pregnancy and newborn outcomes
Publication history
- Received November 21, 2016
- Revised December 10, 2016
- Accepted December 17, 2016
- First published January 10, 2017.
Online issue publication
September 06, 2017
Article Versions
- Previous version (10 January 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/